DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹556 Cr | ₹437 Cr | ₹364 Cr | ₹295 Cr | ₹991 Cr |
What is the latest Total Non-Current Liabilities ratio of DIVIS LABORATORIES ?
Year | Total Non-Current Liabilities |
---|---|
Mar2023 | ₹556 Cr |
Mar2022 | ₹437 Cr |
Mar2021 | ₹364 Cr |
Mar2020 | ₹295 Cr |
Mar2019 | ₹991 Cr |
How is Total Non-Current Liabilities of DIVIS LABORATORIES Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2023 | ₹556 Cr | 27.46 | |
Mar2022 | ₹437 Cr | 19.94 | |
Mar2021 | ₹364 Cr | 23.55 | |
Mar2020 | ₹295 Cr | -70.29 | |
Mar2019 | ₹991 Cr | - |
Compare Total Non-Current Liabilities of peers of DIVIS LABORATORIES
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
DIVIS LABORATORIES | ₹106,204.0 Cr | 4.8% | 18.9% | 23.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹360,452.0 Cr | 1.1% | -6.6% | 56.7% | Stock Analytics | |
CIPLA | ₹113,132.0 Cr | 0.2% | -4.4% | 54.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹103,512.0 Cr | 4.3% | 2.6% | 29.9% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹95,954.5 Cr | 2.2% | -4.6% | 86.6% | Stock Analytics | |
MANKIND PHARMA | ₹94,779.2 Cr | -1.4% | 1.4% | NA | Stock Analytics |
DIVIS LABORATORIES Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
DIVIS LABORATORIES | 4.8% |
18.9% |
23.9% |
SENSEX | 1% |
2.8% |
23.9% |
You may also like the below Video Courses